摘要
There are increasing studies aimed to reveal genomic hallmarks predictive of immune checkpoint blockade(ICB)treatment response,which generated a large number of data and provided an unprecedented opportunity to identify response-related features and evaluate their robustness across cohorts.However,those valuable data sets are not easily accessible to the research community.To take full advantage of existing large-scale immuno-genomic profiles,we developed Immu-Mela(http://bioinfo.vanderbilt.edu/database/Immu-Mela/),a multidimensional immuno-genomic portal that provides interactive exploration of associations between ICB responsiveness and multi-omics features in melanoma,including genetic,transcriptomics,immune cells,and single-cell populations.Immu-Mela also enables integrative analysis of any two genomic features.We demonstrated the value of Immu-Mela by identifying known and novel genomic features associated with ICB response.In addition,Immu-Mela allows users to upload their data sets(unrestricted to any cancer types)and co-analyze with existing data to identify and validate signatures of interest.Immu-Mela reduces barriers between researchers and complex genomic data,facilitating discoveries in cancer immunotherapy.
基金
funding from National Cancer Institute(5U01 CA163056–05,U2C CA233291 and U54CA217450 to Y.S.)
Cancer Center Support Grant(2P30 CA068485-19 to Y.S.)
Funding for open access charge:National Cancer Institute(5U01 CA163056-05 to Y.S.)。
